Kiniksa Pharmaceuticals International, plc financial data

Symbol
KNSA on Nasdaq
Location
London
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 24 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 372% % 5.8%
Quick Ratio 35% % 2.6%
Debt-to-equity 33% % 27%
Return On Equity 11% %
Return On Assets 8.6% %
Operating Margin 11% %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $1,114,000,000 USD 60%
Weighted Average Number of Shares Outstanding, Basic 74,200,924 shares 3.9%
Weighted Average Number of Shares Outstanding, Diluted 78,979,030 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $180,855,000 USD 61%
Revenue from Contract with Customer, Excluding Assessed Tax $677,564,000 USD 60%
Research and Development Expense $96,853,000 USD -13%
Operating Income (Loss) $77,221,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $88,868,000 USD
Income Tax Expense (Benefit) $29,863,000 USD 324%
Net Income (Loss) Attributable to Parent $59,005,000 USD
Earnings Per Share, Basic 0.8 USD/shares
Earnings Per Share, Diluted 0.75 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $165,596,000 USD -9.8%
Cash, Cash Equivalents, and Short-term Investments $414,074,000 USD 70%
Accounts Receivable, after Allowance for Credit Loss, Current $15,594,000 USD -63%
Inventory, Net $54,895,000 USD 108%
Assets, Current $527,177,000 USD 59%
Deferred Income Tax Assets, Net $198,149,000 USD -6.2%
Property, Plant and Equipment, Net $1,943,000 USD 194%
Operating Lease, Right-of-Use Asset $9,807,000 USD -5.5%
Other Assets, Noncurrent $11,307,000 USD 9.6%
Assets $763,633,000 USD 32%
Accounts Payable, Current $2,028,000 USD -0.54%
Employee-related Liabilities, Current $6,629,000 USD -3.7%
Accrued Liabilities, Current $42,020,000 USD 30%
Liabilities, Current $139,184,000 USD 38%
Contract with Customer, Liability, Noncurrent $31,811,000 USD 0%
Operating Lease, Liability, Noncurrent $6,510,000 USD -17%
Other Liabilities, Noncurrent $18,522,000 USD 916%
Liabilities $196,027,000 USD 38%
Accumulated Other Comprehensive Income (Loss), Net of Tax $25,000 USD 85%
Retained Earnings (Accumulated Deficit) $462,138,000 USD 11%
Stockholders' Equity Attributable to Parent $567,606,000 USD 29%
Liabilities and Equity $763,633,000 USD 32%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Par or Stated Value Per Share 0.0003 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $165,596,000 USD -9.8%
Deferred Tax Assets, Valuation Allowance $666,461,000 USD 1.5%
Deferred Tax Assets, Gross $866,908,000 USD -1.4%
Operating Lease, Liability $9,497,000 USD -3.6%
Depreciation $196,000 USD -56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $59,143,000 USD
Lessee, Operating Lease, Liability, to be Paid $10,480,000 USD -6%
Property, Plant and Equipment, Gross $9,173,000 USD 3.6%
Operating Lease, Liability, Current $2,987,000 USD 50%
Lessee, Operating Lease, Liability, to be Paid, Year Two $4,164,000 USD 21%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,480,000 USD 36%
Operating Lease, Weighted Average Discount Rate, Percent 0.0698 pure 1.7%
Deferred Income Tax Expense (Benefit) $4,227,000 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $983,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,563,000 USD -18%
Deferred Tax Assets, Operating Loss Carryforwards $109,363,000 USD 28%
Unrecognized Tax Benefits $32,675,000 USD 144%
Lessee, Operating Lease, Liability, to be Paid, Year Four $193,000 USD -91%
Additional Paid in Capital $1,029,748,000 USD 7.3%
Amortization of Intangible Assets $250,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $198,149,000 USD -6.2%
Share-based Payment Arrangement, Expense $37,003,000 USD 21%